Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial

Clinical Rheumatology

Volumn 34, Issue 9, 2015, Pages 1513-1519

  Duan, Xin Wang ^a   Zhang, Xiu Ling ^a   Mao, Shao Yuan ^a   Shang, Jing Jing ^a   Shi, Xiao Dong ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Iguratimod; Methotrexate; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; IGURATIMOD; METHOTREXATE; ANTIRHEUMATIC AGENT; CHROMONE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DAS28; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; ULCER; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; CHINA; COMBINATION DRUG THERAPY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHINA; CHROMONES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84940435308     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2999-6     Document Type: Article

References (37)

1. Chao C-C, Chen S-J, Adamopoulos IE, Davis N, Hong K, Vu A, Kwan S, Fayadat-Dilman L, Asio A, Bowman EP (2011) Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44(3):243–252
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581
3. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219
4. Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63(4):522–529
5. Gaffo A, Saag KG, Curtis JR (2006) Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63(24):2451–2465
6. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(4):583–589
7. Saunders S, Capell H, Stirling A, Vallance R, Kincaid W, McMahon A, Porter D (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies. Arthritis Rheum 58(5):1310–1317
8. Van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P, Settas L, Bijlsma J, Todesco S, Dougados M (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63(5):508–516
9. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta‐analysis of randomized controlled trials. Arthritis Rheum 66(4):803–812
10. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861–1874
11. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7(1):e30275
12. Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64(9):2824–2835
13. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443
14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Rv V, Sharp J, Perez JL, Spencer‐Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37
15. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17(1):1–9
16. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K (2013) OP0205 efficacy and safety evaluation of iguratimod, a novel anti-rheumatic agent—a double-blind, comparative study of iguratimod-MTX combination in rheumatoid arthritis patients with an inadequate response to MTX. Ann Rheum Dis 71(3):124–125
17. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K (2014) Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 24(3):410–418
18. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M (2013) Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23(3):430–439
19. Lu L, Bao C, Dai M, Jl T, Fan W, Du F, Yang N, Zhao Y, Chen Zw XJ (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Care Res 61(7):979–987
20. Wei Y, Sun X, Hua M, Tan W, Wang F, Zhang M (2014) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int
21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45
22. Yan Q, Du F, Huang X, Fu Q, Chen S, Dai D, Bao C (2014) Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLoS One 9(10):e108273
23. Luo Q, Sun Y, Jin B, Zheng W, Shao F (2014) Iguratimod synergizes with methotrexate to exert anti-inflammatory and bone-protective effect and block the progression of collagen-induced arthritis in mice. Biochem Pharmacol 3(135):2167–0501.1000135
24. Lu L-j, J-l T, Bao C-d, X-h H, Xu SL-y, J-h LX-f, Wu H-x (2008) Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J 121(7):615
25. Yoshizaki K, Nakazawa S, Nishikawa T, Isobe T (2012) P080 pathogenic role of IL-6 on the inducation of acute phase proteins, CRP and SAA in rheumatoid arthritis a chronic inflammatory disease. Cytokine 59(3):544–545
26. Okuda O, Yoshida N, Maini RN (2014) Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate. Google Patents
27. Kremer JM, Blanco R, Brzosko M, Burgos‐Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63(3):609–621
28. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M (2007) Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 17(1):10–16
29. Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K, Miranda‐Carboni GA, Krum SA (2013) ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res 28(2):283–290
30. Mucke H (2012) Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc) 48(9):577–586
31. Du F, Lu L-j FQ, Dai M, J-l T, Fan W, S-l C, Ye P, Shen N, X-f H (2008) T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther 10(6):R136
32. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64(5):640–647
33. Bluett J, Ibrahim I, Plant D, Hyrich K, Morgan A, Wilson A, Isaacs J, Gaston H, Mulherin D, Price T (2014) Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics J 14(2):171–175
34. Kushner I (1991) C-reactive protein in rheumatology. Arthritis Rheum 34(8):1065–1068
35. Brigden ML (1999) Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 60(5):1443–1450
36. Nielung L, Christensen R, Danneskiold-Samsøe B, Bliddal H, Holm CC, Ellegaard K, Slott Jensen H, Bartels EM (2015) Validity and agreement between the 28-joint disease activity score based on C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Arthritis Rheum 2015
37. Tamhane A, Redden DT, McGwin G, Brown EE, Westfall AO, Reynolds RJ, Hughes LB, Conn DL, Callahan LF, Jonas BL (2013) Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. J Rheumatol 40(11):1812–1822